Enovis (NYSE:ENOV) Insider Oliver Engert Acquires 1,000 Shares

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the stock in a transaction on Monday, June 15th. The shares were bought at an average price of $20.92 per share, for a total transaction of $20,920.00. Following the acquisition, the insider owned 53,640 shares in the company, valued at $1,122,148.80. The trade was a 1.90% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average cost of $23.00 per share, for a total transaction of $23,000.00.
• On Monday, June 1st, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $22.22 per share, for a total transaction of $22,220.00.

Enovis Stock Performance

Shares of NYSE ENOV opened at $21.56 on Wednesday. The company has a 50-day simple moving average of $23.97 and a 200-day simple moving average of $24.44. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The company has a market cap of $1.24 billion, a PE ratio of -1.08 and a beta of 1.38. Enovis Corporation has a 12 month low of $20.55 and a 12 month high of $36.82.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts anticipate that Enovis Corporation will post 3.65 earnings per share for the current year.

Hedge Funds Weigh In On Enovis

Several hedge funds have recently modified their holdings of the company. Arax Advisory Partners acquired a new stake in Enovis in the 4th quarter valued at about $29,000. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the period. GAMMA Investing LLC lifted its position in shares of Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after purchasing an additional 1,446 shares in the last quarter. Danske Bank A S acquired a new stake in shares of Enovis during the 3rd quarter valued at $64,000. Finally, iSAM Funds UK Ltd purchased a new position in Enovis in the third quarter valued at about $80,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on ENOV. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. William Blair began coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Evercore reissued an “outperform” rating and issued a $36.00 price target on shares of Enovis in a report on Friday, May 8th. Zacks Research cut shares of Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Wells Fargo & Company lowered their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.50.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.